Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENGRUI PHARMA's Hemofiltration Replacement Fluid of Sodium Citrate Approved for Launch
Recommend 5 Positive 8 Negative 3 |
||||
|
||||
|
HENGRUI PHARMA (01276.HK)'s subsidiary, Fujian Shengdi Pharmaceutical, received notification from the National Medical Products Administration (NMPA) approving the market launch of its hemofiltration replacement fluid of sodium citrate, as announced by HENGRUI PHARMA. The medication can be used as a replacement fluid for continuous renal replacement therapy (CRRT) employing regional citrate anticoagulation. Citrate is particularly suitable for situations where systemic anticoagulation with heparin is contraindicated, such as in patients with increased bleeding risk. The product's approval is considered equivalent to passing the generic drug quality and efficacy consistency evaluation, the Company added. As of now, the total R&D investment for the hemofiltration replacement fluid of sodium citrate project was approx. RMB8.57 million. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
